Versant Capital Management, Inc Alnylam Pharmaceuticals, Inc. Transaction History
Versant Capital Management, Inc
- $431 Million
- Q3 2024
A detailed history of Versant Capital Management, Inc transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Versant Capital Management, Inc holds 107 shares of ALNY stock, worth $27,596. This represents 0.01% of its overall portfolio holdings.
Number of Shares
107
Previous 62
72.58%
Holding current value
$27,596
Previous $15,000
93.33%
% of portfolio
0.01%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding ALNY
# of Institutions
639Shares Held
108MCall Options Held
1.15MPut Options Held
1.07M-
Capital World Investors Los Angeles, CA16.5MShares$4.26 Billion0.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.6MShares$3.26 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.46 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA5.24MShares$1.35 Billion0.31% of portfolio
-
Wellington Management Group LLP Boston, MA4.95MShares$1.28 Billion0.24% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $31.7B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...